Iron deficiency in the practice of a gynecologist: therapeutic efficacy

Introduction. Iron deficiency (ID) of varying severity is the most common and rather serious extra-gynecological complication adenomyosis resulting from meno/metrorrhagia intensity, up to abnormal uterine bleeding requiring surgical hemostasis. Taking into account chronic course disease, complexity radical therapy as well a systemic effect ID also particularly affecting reproductive system, an issue sufficient timely correction in patients with remains relevant. Aim: study efficacy drug containing ferrous fumarate folic acid adenomyosis. Materials Methods . An observational was conducted, which included 90 isolated severity: 30 degree 1 (group 1), 2 2), women 3–4 3). All received plus for days. To identify variant, level serum ferritin, iron, transferrin, total iron-binding capacity blood (TIBC), clinical test parameters such hemoglobin level, erythrocyte count, hematocrit, mean corpuscular volume (MCV), concentration (MCHC) were measured. Results. A significant increase ferrokinetic found all patient groups. The clinically important dynamics noted iron TIBC. For instance, after therapy, increased group 11.0 ± 0.6 μmol/l 15.0 1.1 μmol/l, – 9.0 1.6 14 .0 0.8 3 7.0 1.3 12.0 (p < 0.05). In addition, decreased TIBC 3: 68.0 1.8 down 58.0 1.7 0.05); groups tended insignificantly decrease. Conclusion use preparation along can effectively correct background intensity. earlier longer administration preparations laboratory parameter monitoring recommended achieve more pronounced effect.